Researchers are a step closer to revolutionizing how doctors use radiotherapy to treat patients with muscle-invasive bladder ...
Parade on MSN6d
This Is One of the Most Common Signs of Bladder Cancer, According to a UrogynecologistDr. Kobashi says that the most common symptom of bladder cancer is blood in urine. The blood can range from bright red to a ...
Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...
The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...
The subtypes investigated in bladder cancer were CK19, CK20 and CK7 IHC/RT-PCR CK20: 56–46% [98,99]; CK7: 100% [99]; CK1: 93.1% [101] Association of CK19 with UPII detected pN0 patients with ...
With its lead candidate in a phase 3 trial for a rare eye cancer, Aura Biosciences is looking to expand the drug into a more ...
Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...
The FDA has accepted a new drug application for the intravesical solution of UGN-102 in low-grade intermediate-risk ...
Whether extended lymphadenectomy is associated with improved disease-free and overall survival, as compared with standard lymphadenectomy, among patients with localized muscle-invasive bladder ...
It works by targeting tumours with X-ray radiation, killing cancer cells by irreversibly ... it is possible to deliver ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback